ES2060020T3 - Derivados de pirrolidina. - Google Patents

Derivados de pirrolidina.

Info

Publication number
ES2060020T3
ES2060020T3 ES90302269T ES90302269T ES2060020T3 ES 2060020 T3 ES2060020 T3 ES 2060020T3 ES 90302269 T ES90302269 T ES 90302269T ES 90302269 T ES90302269 T ES 90302269T ES 2060020 T3 ES2060020 T3 ES 2060020T3
Authority
ES
Spain
Prior art keywords
formula
pirrolidine
derivatives
pirrolidine derivatives
pirazinil
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90302269T
Other languages
English (en)
Inventor
Peter Edward Dr Cross
Alexander Roderick D Mackenzie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10653525&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2060020(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2060020T3 publication Critical patent/ES2060020T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

ANTAGONISTAS RECEPTORES DE MUSCARINICO DE PIROLIDINA, PARTICULARMENTE UTILES EN EL TRATAMIENTO DEL SINDROME DE VIENTRE IRRITABLE DE FORMULA (I) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, DONDE Y ES UN ENALCE DIRECTO DE FORMULA (2) R ES -CNO -CONH2; Y R'' ES UN GRUPO DE FORMULA (3) DONDE X Y X'' SON CADA UNO INDEPENDIENTEMENTE O O CH2; M ES 1, 2 O 3; Y "HET" ES PIRIDIL, PIRAZINIL O TIENIL.
ES90302269T 1989-03-17 1990-03-02 Derivados de pirrolidina. Expired - Lifetime ES2060020T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898906166A GB8906166D0 (en) 1989-03-17 1989-03-17 Therapeutic agents

Publications (1)

Publication Number Publication Date
ES2060020T3 true ES2060020T3 (es) 1994-11-16

Family

ID=10653525

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90302269T Expired - Lifetime ES2060020T3 (es) 1989-03-17 1990-03-02 Derivados de pirrolidina.

Country Status (37)

Country Link
US (1) US5096890B1 (es)
EP (1) EP0388054B1 (es)
JP (2) JPH0764809B2 (es)
KR (2) KR920008166B1 (es)
CN (1) CN1023007C (es)
AT (1) ATE96783T1 (es)
AU (1) AU614224B2 (es)
BA (1) BA98300A (es)
CA (1) CA2012295C (es)
CL (1) CL2003002756A1 (es)
CY (2) CY1812A (es)
CZ (1) CZ280053B6 (es)
DD (1) DD292911A5 (es)
DE (2) DE69004302T2 (es)
DK (1) DK0388054T3 (es)
EG (1) EG18951A (es)
ES (1) ES2060020T3 (es)
FI (1) FI95573C (es)
GB (1) GB8906166D0 (es)
HK (1) HK130294A (es)
HU (2) HU217433B (es)
IE (1) IE62515B1 (es)
IL (1) IL93694A (es)
LU (1) LU91161I2 (es)
MX (1) MX9319890A (es)
MY (1) MY105527A (es)
NL (1) NL300191I2 (es)
NO (2) NO176316C (es)
NZ (1) NZ232958A (es)
PL (1) PL164136B1 (es)
PT (1) PT93443B (es)
RU (2) RU1833374C (es)
SG (1) SG143394G (es)
SK (1) SK278434B6 (es)
UA (1) UA18263A (es)
YU (1) YU47587B (es)
ZA (1) ZA901982B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932594A (en) * 1988-11-01 1999-08-03 Pfizer, Inc. Muscarinic receptor antagonists
GB8825505D0 (en) * 1988-11-01 1988-12-07 Pfizer Ltd Therapeutic agents
GB8928042D0 (en) * 1989-12-12 1990-02-14 Pfizer Ltd Muscarinic receptor antagonists
US5607950A (en) * 1990-01-06 1997-03-04 Pfizer Inc. Muscarinic receptor antagonists
US5486527A (en) * 1990-01-06 1996-01-23 Pfizer Inc. Anticholinergic agents
PT637306E (pt) * 1992-04-23 2001-10-30 Merrell Pharma Inc 4-imidometil-1-¬2'-fenil-2'-oxoetil|-piperidinas como antagonistas 5ht2 da serotonina sua preparacao e sua utilizacao em terapeutica
GB9400600D0 (en) * 1994-01-14 1994-03-09 Pfizer Ltd Treatment of motion seckness
US5639763A (en) * 1994-03-01 1997-06-17 Fmc Corporation Insecticidal N-(substituted arylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
US6017931A (en) * 1994-03-01 2000-01-25 Fmc Corporation Insecticidal compositions containing n-(substituted phenylmethyl)-4-[bis(substituted phenyl)methyl]piperidines
BR9508436A (pt) * 1994-07-27 1998-07-14 Procter & Gamble Dihidro benzofurando e compostos correlacionados úteis como agentes anti-inflamatórios
US5656661A (en) * 1994-07-27 1997-08-12 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
GB9518953D0 (en) * 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
US5672620A (en) * 1996-02-01 1997-09-30 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
US5684031A (en) * 1996-02-01 1997-11-04 The Procter & Gamble Company Dihydrobenzofuran and related compounds useful as anti-inflammatory agents
JP4167302B2 (ja) * 1996-12-02 2008-10-15 杏林製薬株式会社 新規ｎ―置換ピロリジン誘導体及びその製造法
US6131129A (en) * 1997-07-30 2000-10-10 Sony Corporation Of Japan Computer system within an AV/C based media changer subunit providing a standarized command set
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
US6653339B2 (en) 2001-08-15 2003-11-25 Pfizer Inc. Method of treating irritable bowel syndrome
JP3981357B2 (ja) * 2001-10-26 2007-09-26 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 第４級アンモニウム化合物および抗ムスカリン剤としてのそれらの使用
SE0103668D0 (sv) * 2001-11-02 2001-11-02 Astrazeneca Ab Method for the treatment of overactive blader
JP2005511582A (ja) * 2001-11-05 2005-04-28 ファルマシア アンド アップジョン カンパニー リミティド ライアビリティー カンパニー 抗ムスカリン・エアゾール
GB0129962D0 (en) * 2001-12-14 2002-02-06 Pfizer Ltd Method of treatment
GB0207104D0 (en) * 2002-03-26 2002-05-08 Pfizer Ltd Stable hydrate of a muscarinic receptor antagonist
EA200500173A1 (ru) 2002-07-08 2005-08-25 Рэнбакси Лабораториз Лимитед Производные 3,6-дизамещенного азабицикло[3.1.0]гексана в качестве антагонистов мускариновых рецепторов
EP1546098B1 (en) 2002-07-31 2008-05-28 Ranbaxy Laboratories Limited 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists
EP1545508A4 (en) 2002-08-09 2009-11-25 Ranbaxy Lab Ltd 3,6-DISUBSTITUTED AZABICYCLO ¬3.1.0 HEXANE DERIVATIVES AS USEFUL AS MUSCARINIC RECEPTOR AGONISTS
ATE423769T1 (de) 2002-08-23 2009-03-15 Ranbaxy Lab Ltd Fluor- und sulfonylaminohaltige, 3,6- disubstituierte azabicyclo 3.1.0 hexanderivate als muscarinrezeptorantagonisten
TW200412945A (en) * 2002-10-25 2004-08-01 Upjohn Co Quaternary ammonium compounds
TW200800953A (en) 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
US7232835B2 (en) 2002-12-10 2007-06-19 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo derivatives as muscarinic receptor antagonists
US7465751B2 (en) 2002-12-23 2008-12-16 Ranbaxy Laboratories Limited 1-substituted-3-pyrrolidine derivatives as muscarinic receptor antagonists
AU2002347553A1 (en) 2002-12-23 2004-07-14 Ranbaxy Laboratories Limited Flavaxate derivatives as muscarinic receptor antagonists
US7488748B2 (en) 2003-01-28 2009-02-10 Ranbaxy Laboratories Limited 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists
JP4767842B2 (ja) 2003-04-01 2011-09-07 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有するジアリールメチル化合物および関連化合物
EP1618091A1 (en) 2003-04-09 2006-01-25 Ranbaxy Laboratories, Ltd. Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089899A1 (en) 2003-04-10 2004-10-21 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
ATE362364T1 (de) 2003-04-10 2007-06-15 Ranbaxy Lab Ltd Substituierte azabicyclo hexane derivate als muscarin rezeptor antagonisten
CA2522071A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
WO2004091597A2 (en) * 2003-04-15 2004-10-28 Pharmacia & Upjohn Company Llc Method of treating irritable bowel syndrome (ibs)
BRPI0409370A (pt) * 2003-04-15 2006-04-25 Pharmacia & Upjohn Co Llc compostos de amÈnio quaternário e seus usos como agentes antimuscarìnicos
CA2522666A1 (en) * 2003-04-18 2004-10-28 Pharmacia & Upjohn Company Llc Combination therapies for chronic obstructive pulmonary disease (copd)
TW200510298A (en) * 2003-06-13 2005-03-16 Theravance Inc Substituted pyrrolidine and related compounds
US7368463B2 (en) 2003-07-11 2008-05-06 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
JP2007528414A (ja) * 2004-03-11 2007-10-11 セラヴァンス， インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なジフェニルメチル化合物
EP1723142A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Diphenylmethyl compounds useful as muscarinic receptor antagonists
WO2005092341A1 (en) * 2004-03-22 2005-10-06 Ranbaxy Laboratories Limited Combination therapy for lower urinary tract symptoms
AU2006305619A1 (en) 2005-10-19 2007-04-26 Ranbaxy Laboratories Limited Pharmaceutical compositions of muscarinic receptor antagonists
WO2007076159A2 (en) * 2005-12-27 2007-07-05 Teva Pharmaceutical Industries Ltd. Pure darifenacin hydrobromide substantially free of oxidized darifenacin and salts thereof and processes for the preparation thereof
AR062676A1 (es) * 2006-09-07 2008-11-26 Medichem Sa Procedimiento mejorado para preparar compuestos de pirrolidina 1,3-disustituidas
US20100112061A1 (en) * 2006-12-13 2010-05-06 William Baker Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis
WO2008100651A2 (en) * 2007-01-05 2008-08-21 Dr. Reddy's Laboratories Ltd. Preparation of darifenacin and its salts
RU2452728C2 (ru) * 2007-02-23 2012-06-10 Тереванс, Инк. Четвертичные аммониевые дифенилметилсоединения, применимые в качестве антагонистов мускариновых рецепторов
WO2008126106A2 (en) * 2007-04-16 2008-10-23 Manne Satyanarayana Reddy Novel and improved processes for the preparation of intermediates of darifenacin, darifenacin and its pharmaceutically acceptable salts
WO2009007853A2 (en) * 2007-06-08 2009-01-15 Actavis Group Ptc Ehf Novel polymorphs of darifenacin free base and its hydrobromide salt
WO2008152497A1 (en) * 2007-06-15 2008-12-18 Medichem, S.A. Method for determining enantiomeric purity of darifenacin and intermediates
WO2009006413A1 (en) * 2007-06-30 2009-01-08 Auspex Pharmaceuticals, Inc. Substituted pyrrolidines
US20090018346A1 (en) * 2007-07-13 2009-01-15 Medichem, S.A. Amorphous Form Of Darifenacin Hydrobromide And Processes For The Preparation Thereof
CZ200845A3 (cs) * 2008-01-28 2009-09-02 Zentiva, A. S. Zpusob prípravy Darifenacinu
WO2009125430A2 (en) * 2008-03-17 2009-10-15 Matrix Laboratoires Limited Improved process for producing darifenacin
CN101983187A (zh) * 2008-04-02 2011-03-02 株式会社钟化 (s)-3-(1-氰基-1，1-二苯基甲基)吡咯烷的制备方法
US20110144354A1 (en) * 2008-09-22 2011-06-16 Watson Pharma Private Limited Process for Preparation of Darifenacin and Intermediates Used in the Process
EP2236509A1 (en) 2009-04-01 2010-10-06 Ragactives, S.L. Method for obtaining 1,3-difunctionalized pyrrolidine derivatives
NZ596492A (en) 2009-05-15 2013-08-30 Redx Pharma Ltd Redox drug derivatives
WO2011070419A1 (en) 2009-12-10 2011-06-16 Aurobindo Pharma Limited An improved process for the preparation of darifenacin hydrobromide
AU2011245499B2 (en) 2010-04-30 2014-09-25 Merck Sharp & Dohme Corp. Novel beta 3 adrenergic receptor agonists
CN101857581A (zh) * 2010-06-22 2010-10-13 浙江美诺华药物化学有限公司 一种制备达非那新中间体5-(2-溴乙基)-2,3-二氢-1-苯并呋喃的方法
WO2011161504A1 (en) 2010-06-23 2011-12-29 Micro Labs Limited Extended release formulations containing darifenacin or pharmaceutically acceptable salts thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1057145A (en) * 1963-08-16 1967-02-01 Bellon Labor Sa Roger Phenylcyclohexylacetonitrile derivatives
US4002766A (en) * 1974-12-26 1977-01-11 A. H. Robins Company, Incorporated Antiarrhythmia methods
US4242261A (en) * 1979-07-19 1980-12-30 A. H. Robins Company, Inc. Production of methylene-cycloamines
IL76583A (en) * 1984-10-19 1988-08-31 Robins Co Inc A H 1-(aminoalkyl)-alpha'alpha-diaryl pyrrolidinyl,piperidino and homopiperidino acetamides and acetonitriles and pharmaceutical compositions containing them
US4594343A (en) * 1984-10-19 1986-06-10 Shanklin Jr James R 1-[(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl]-α,α-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
EP0235463A3 (en) * 1985-12-20 1990-01-17 A.H. ROBINS COMPANY, INCORPORATED (a Delaware corporation) N-substituted-arylalkyl and arylalkylene piperidines as cardiovascular antihistaminic and antisecretory agents
IN163948B (es) * 1986-01-17 1988-12-10 Robins Co Inc A H

Also Published As

Publication number Publication date
FI95573B (fi) 1995-11-15
GB8906166D0 (en) 1989-05-04
MY105527A (en) 1994-10-31
CZ129590A3 (en) 1995-05-17
NO176316C (no) 1995-03-15
DE69004302T2 (de) 1994-02-24
PT93443A (pt) 1990-11-07
HU217433B (hu) 2000-01-28
BA98300A (bs) 2001-09-14
HU901580D0 (en) 1990-06-28
CY2005005I1 (el) 2010-07-28
KR920008166B1 (ko) 1992-09-24
DK0388054T3 (da) 1993-12-06
KR960015142B1 (ko) 1996-11-01
CY2005005I2 (el) 2010-07-28
HUT58313A (en) 1992-02-28
NO2005008I1 (en) 2005-04-11
PT93443B (pt) 1996-02-29
IE62515B1 (en) 1995-02-08
CY1812A (en) 1995-10-20
AU614224B2 (en) 1991-08-22
JPH0764809B2 (ja) 1995-07-12
LU91161I2 (fr) 2005-06-13
EP0388054B1 (en) 1993-11-03
HK130294A (en) 1994-12-02
NL300191I1 (nl) 2005-07-01
HU211640A9 (en) 1995-12-28
MX9319890A (es) 1993-08-01
RU2015965C1 (ru) 1994-07-15
CL2003002756A1 (es) 2005-02-11
EG18951A (en) 1994-03-30
SG143394G (en) 1995-01-13
FI95573C (fi) 1996-02-26
NO901241L (no) 1990-09-18
NZ232958A (en) 1992-05-26
AU5140290A (en) 1990-09-20
UA18263A (uk) 1997-12-25
NO901241D0 (no) 1990-03-16
KR900014367A (ko) 1990-10-23
DE122005000022I1 (de) 2005-08-04
DD292911A5 (de) 1991-08-14
YU47587B (sh) 1995-10-24
ATE96783T1 (de) 1993-11-15
RU1833374C (ru) 1993-08-07
IL93694A (en) 1994-08-26
US5096890A (en) 1992-03-17
DE122005000022I2 (de) 2006-02-02
CA2012295C (en) 1996-11-12
NO176316B (no) 1994-12-05
US5096890B1 (en) 1995-03-28
IE900955L (en) 1990-09-17
YU52790A (sh) 1992-07-20
CN1045580A (zh) 1990-09-26
DE69004302D1 (de) 1993-12-09
IL93694A0 (en) 1990-12-23
SK129590A3 (en) 1997-05-07
FI901333A0 (fi) 1990-03-16
JPH07149640A (ja) 1995-06-13
NO2005008I2 (no) 2006-11-27
SK278434B6 (en) 1997-05-07
JPH02282360A (ja) 1990-11-19
CN1023007C (zh) 1993-12-08
ZA901982B (en) 1991-10-30
CA2012295A1 (en) 1990-09-17
EP0388054A1 (en) 1990-09-19
NL300191I2 (nl) 2005-08-01
CZ280053B6 (cs) 1995-10-18
PL164136B1 (pl) 1994-06-30

Similar Documents

Publication Publication Date Title
ES2060020T3 (es) Derivados de pirrolidina.
ES2108700T3 (es) Derivados de diazabiciclonolilo como antagonistas del receptor 5-ht3.
ES2113368T3 (es) Antagonistas de serotonina.
CO4180381A1 (es) Derivados opticamente activos de 2-imidazolin-5-onas y 2- imidazolina-5-tionas fungicidas
NO960630D0 (no) Heterocykler anvendelige som neurokinin antagonister
ES2159749T3 (es) Derivados de bencilamino-2-metil-propanamidas 2-(4-sustituidas).
ES2160106T3 (es) Derivados de la quinazolina.
NO901760L (no) Substituerte arylureaforbindelser som soetningsmidler med hoey styrke.
ES2132882T3 (es) Compuestos de 1-aril-2-acilamino-etano y su uso como antagonistas de neuroquinina 1.
ES2120025T3 (es) Derivados de xantina utilizados como antagonistas de receptores de adenosina a1.
DE68920913D1 (de) Serotonin-Antagonisten.
ES2054186T3 (es) Composicion antihepatopatica.
ATE113949T1 (de) Alpha-adrenergische rezeptorantagonisten.
ATE106886T1 (de) Azabicycloamide und -ester als 5-ht3-receptor- antagonisten.
ATE114310T1 (de) Alpha-adrenergische rezeptorantagonisten.
DE59007354D1 (de) Monohydrochlorid und Monomethansulfonat von Amonafide.
DK286090D0 (da) Alfa-adrenerge receptorantagonister

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 388054

Country of ref document: ES

SPCG Supplementary protection certificate granted

Free format text: PRODUCT NAME: HIDROBROMURO DE DARIFENACINA (EMSELEX); REG. NO/DATE: EU/1/04/294/001-012 20041022

Spc suppl protection certif: C200500020

Filing date: 20050401

Extension date: 20150302

Effective date: 20070521